Additionally, there are important concerns regarding long-term safety
Participants were randomized 2:1:1:1:1:2:2 to receive placebo or retatrutide at 1 mg, 4 mg (starting at 2 mg), 4 mg (starting at 4 mg), 8 mg (starting at 2 mg), 8 mg (starting at 4 mg), or 12 mg (starting at 2 mg) administered subcutaneously once weekly for 48 weeks
The Phase 3 TRIUMPH-4 data extends to 68 weeks and shows 28.7% weight loss, suggesting the drug continues working well beyond the Phase 2 timeframe
Pills eliminate the need for refrigeration and injection supplies, but pricing and insurance coverage will remain critical factors
Chronic stress keeps your body in fight or flight mode, with elevated levels of stress hormones that cause metabolic disease and obesity, and undermine your immune function